WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018044105) IL-21 (HETERODIMERIC FC-FUSED IL-21) FUSED TO IMMUNOGLOBULIN HEAVY CHAIN CONSTANT REGION HETERODIMER (HETERODIMERIC FC), AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/044105    International Application No.:    PCT/KR2017/009570
Publication Date: 08.03.2018 International Filing Date: 31.08.2017
IPC:
C07K 14/54 (2006.01), A61K 38/20 (2006.01), A61K 45/06 (2006.01), A61K 47/68 (2017.01)
Applicants: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION [KR/KR]; Korea University 145, Anam-ro Seongbuk-gu Seoul 02841 (KR).
AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION [KR/KR]; 206, World cup-ro, Yeongtong-gu Suwon-si Gyeonggi-do 16499 (KR)
Inventors: LEE, Kyung-Mi; (KR).
LIM, Seon Ah; (KR).
KIM, Yong Sung; (KR).
KIM, Ye Jin; (KR)
Agent: LEE, Cheo Young; (KR).
CHANG, Je Hwan; (KR)
Priority Data:
10-2016-0113452 02.09.2016 KR
Title (EN) IL-21 (HETERODIMERIC FC-FUSED IL-21) FUSED TO IMMUNOGLOBULIN HEAVY CHAIN CONSTANT REGION HETERODIMER (HETERODIMERIC FC), AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
(FR) IL -21 (IL -21 FUSIONNÉ À UN FC HÉTÉRODIMÈRE) FUSIONNÉ À UN HÉTÉRODIMÈRE DE RÉGION CONSTANTE DE CHAÎNE LOURDE D'IMMUNOGLOBULINE (FC HÉTÉRODIMÈRE), ET COMPOSITION PHARMACEUTIQUE LE COMPRENANT
(KO) 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
Abstract: front page image
(EN)The present invention relates to: a heterodimer fusion protein (heterodimeric Fc-fused protein) containing first and second Fc regions of an immunoglobulin heavy chain constant region pair and in which IL-21 is bound to the N-terminus and/or C-terminus of the first and/or second Fc region(s), and characterized in that CH3 domains of the first and second Fc regions are modified such that the formation of a heterodimer can be promoted; and a pharmaceutical composition containing the heterodimeric Fc-fused protein. When the immunoglobulin heavy chain constant region heterodimeric Fc-fused protein according to the present invention is used, the in vivo half-life of IL-21 included in the heterodimeric Fc-fused protein can be remarkably increased.
(FR)La présente invention concerne : une protéine de fusion hétérodimère (protéine fusionnée Fc hétérodimère) contenant des première et seconde régions Fc d'une paire de régions constantes de chaîne lourde d'immunoglobuline et dans laquelle IL -21 est lié à l'extrémité N-terminale et/ou C-terminale de la première et/ou de la seconde région(s) Fc, et caractérisé en ce que les domaines CH3 des première et seconde régions Fc sont modifiés de telle sorte que la formation d'un hétérodimère peut être favorisée ; et une composition pharmaceutique contenant la protéine fusionnée Fc hétérodimère. Lorsque la protéine fusionnée Fc hétérodimère de région constante de chaîne lourde d'immunoglobuline selon la présente invention est utilisée, la demi-vie in vivo de IL-21 incluse dans la protéine fusionnée Fc hétérodimère peut être augmentée de manière remarquable.
(KO)본 발명은 항체(immunoglobulin)의 중쇄불변부위 쌍의 제1 Fc 영역 및 제2 Fc 영역을 포함하고, 상기 제1 Fc 영역 및/또는 제2 Fc 영역의 N-말단 또는 C-말단 중 하나 이상의 말단에 IL-21이 결합되어 있는 이종이중체-융합단백질(heterodimeric Fc-fused protein)에 있어서, 상기 제1 Fc 영역 및 제2 Fc 영역은 이종이중체(heterodimer)의 형성이 촉진되도록 CH3 도메인이 변이된 것임을 특징으로 하는 이종이중체-융합단백질(heterodimeric Fc-fused protein) 및 상기 이종이중체-융합단백질을 포함하는 약제학적 조성물에 대한 것이다. 본 발명에 따른 항체 중쇄불변부위 이종이중체-융합단백질을 이용할 경우, 상기 이종이중체-융합단백질에 포함된 IL-21의 체내 반감기가 현저하게 증가될 수 있는 장점이 있다.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Korean (KO)
Filing Language: Korean (KO)